Edwards Lifesciences Corp Total Liabilities
Edwards Lifesciences Corp total liabilities. Based on the latest financial reports, Edwards Lifesciences Corp (EW) has total liabilities worth $3.14 Billion USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Edwards Lifesciences Corp to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Edwards Lifesciences Corp (1999–2025)
Total liabilities of Edwards Lifesciences Corp from 1999 to 2025. This chart illustrates how Edwards Lifesciences Corp's total liabilities have evolved over time, based on quarterly financial data. Explore Edwards Lifesciences Corp (EW) long-term investment share to see how much of total assets are deployed in long-term investments.
Edwards Lifesciences Corp Competitors by Total Liabilities
The table below lists competitors of Edwards Lifesciences Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Vale S.A.
SA:VALE3
|
Brazil | R$52.29 Billion |
|
Infosys Limited
NSE:INFY
|
India | Rs6.65 Billion |
|
Thomson Reuters Corp
TO:TRI
|
Canada | CA$6.95 Billion |
|
L3Harris Technologies Inc
NYSE:LHX
|
USA | $22.09 Billion |
|
Constellation Software Inc.
TO:CSU
|
Canada | CA$11.22 Billion |
|
Deutsche Bank Aktiengesellschaft
F:DBK
|
Germany | €1.40 Trillion |
|
WuXi AppTec Co Ltd
SHG:603259
|
China | CN¥23.41 Billion |
|
Thales S.A.
PA:HO
|
France | €31.72 Billion |
Liability Composition Analysis (1999–2025)
This chart breaks down Edwards Lifesciences Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Edwards Lifesciences Corp assets under control.
Liquidity & Leverage Metrics
Edwards Lifesciences Corp Total Liabilities Ratios Explained
Edwards Lifesciences Corp total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.30 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Edwards Lifesciences Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Edwards Lifesciences Corp (1999–2025)
The table below shows the annual total liabilities of Edwards Lifesciences Corp from 1999 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $3.36 Billion | +12.27% |
| 2024-12-31 | $2.99 Billion | +13.19% |
| 2023-12-31 | $2.64 Billion | +6.36% |
| 2022-12-31 | $2.49 Billion | -6.78% |
| 2021-12-31 | $2.67 Billion | +0.15% |
| 2020-12-31 | $2.66 Billion | +13.80% |
| 2019-12-31 | $2.34 Billion | +7.17% |
| 2018-12-31 | $2.18 Billion | -19.19% |
| 2017-12-31 | $2.70 Billion | +42.88% |
| 2016-12-31 | $1.89 Billion | +21.51% |
| 2015-12-31 | $1.56 Billion | +16.75% |
| 2014-12-31 | $1.33 Billion | +14.36% |
| 2013-12-31 | $1.17 Billion | +57.03% |
| 2012-12-31 | $742.20 Million | +15.50% |
| 2011-12-31 | $642.60 Million | +40.00% |
| 2010-12-31 | $459.00 Million | +0.31% |
| 2009-12-31 | $457.60 Million | -12.24% |
| 2008-12-31 | $521.40 Million | +2.22% |
| 2007-12-31 | $510.10 Million | +2.55% |
| 2006-12-31 | $497.40 Million | -7.74% |
| 2005-12-31 | $539.10 Million | +11.25% |
| 2004-12-31 | $484.60 Million | +3.92% |
| 2003-12-31 | $466.30 Million | -0.53% |
| 2002-12-31 | $468.80 Million | -8.79% |
| 2001-12-31 | $514.00 Million | -20.68% |
| 2000-12-31 | $648.00 Million | +204.23% |
| 1999-12-31 | $213.00 Million | -- |
About Edwards Lifesciences Corp
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to t… Read more